At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Dalbavancin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-Positive Organisms
Durata Therapeutics Inc., an affiliate of Allergan plc·interventional·Posted Feb 18, 2016·Updated Jan 4, 2019
In Brief
A Phase 2 clinical trial evaluating Dalbavancin and Comparator for Osteomyelitis. Completed, enrolled 80 participants across 1 site.
Detailed Summary
This clinical study will be a single-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteomyelitis
CountriesUkraine
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartMar 2016
Primary CompletionDec 2017
TodayJul 2026
First PostedFeb 18, 2016
Enrollment StartMar 15, 2016
Primary CompletionDec 12, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.4 years ago
Interventions
Dalbavancindrug
Comparatordrug